Compare Cognizant Technology Solutions Corp (CTSH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Recursion Pharmaceuticals Inc — how do they compare? Cognizant Technology Solutions Corp trades at $60.12 (market cap $25.71B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Cognizant Technology Solutions Corp is far larger — about 11.1× Recursion Pharmaceuticals Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.31% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| CTSH | RXRX | |
|---|---|---|
Market Cap | $25.71B | $2.31B |
Volume | 5,152,376 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $86.70 | $6.79 |
52-Week Low | $38.73 | $2.84 |
Typical Hold Time | 57 Days | 22 Days |
Enterprise Value | $26.75B | $1.83B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $60.01, up 4.88% on the day, with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with a P/E of 12.25 and net income margin of 10.26%, while revenue grew to $21.11B in 2025. Analyst consensus is mixed with a $64.25 price target, and the company continues to gain recognition for AI-driven initiatives and workplace excellence.
CTSH presents a balanced outlook with undervalued metrics and strong cash flow, but faces headwinds from technical bearishness and competitive IT spending pressures. The upcoming Q3 2026 earnings on October 29, 2026, will be critical for confirming growth trajectory amid evolving AI integration strategies.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
